Item 5.07 Submission of Matters to a Vote of Security Holders.

The 2023 Annual Meeting of Stockholders (the "Annual Meeting") of Brainstorm Cell Therapeutics Inc. (the "Company") was held virtually via the internet on January 10, 2023 to consider and vote on the proposals set forth below, each of which is described in greater detail in the Company's definitive proxy statement filed with the U.S. Securities and Exchange Commission on December 13, 2022. The following actions were taken at the Annual Meeting:





1. The seven nominees (listed below) for election to the Company's Board of
Directors (the "Board") were elected to hold office until the next annual
meeting of stockholders and until their successors are duly elected and
qualified or until their earlier resignation or removal, based upon the
following votes:



                                      Votes      Votes                    Broker
                        Votes For    Withheld   Against   Abstentions   Non-Votes
Dr. Irit Arbel          10,568,981   226,705      N/A         N/A       13,073,706
Dr. June S. Almenoff    10,481,733   313,953      N/A         N/A       13,073,706
Dr. Anthony Polverino   10,621,912   173,774      N/A         N/A       13,073,706
Dr. Jacob Frenkel       10,637,258   158,428      N/A         N/A       13,073,706
Malcolm Taub            10,516,216   279,470      N/A         N/A       13,073,706
Uri Yablonka            10,597,289   198,397      N/A         N/A       13,073,706
Dr. Menghisteab Bairu   10,652,336   143,350      N/A         N/A       13,073,706

2. The proposal to ratify the appointment of Brightman Almagor Zohar & Co., a Firm in the Deloitte Global Network, as the Company's independent registered public accounting firm for the Company's current fiscal year was approved, based upon the following votes:





Votes For    Votes Withheld   Votes Against   Abstentions   Broker Non-Votes
23,320,844        N/A            482,449        66,099            N/A

© Edgar Online, source Glimpses